Site of localization M. hominis is primarily an opportunistic pathogen of the genitourinary tract. It is capable of infecting human beings as well as non-human primates.
Mycoplasma hominis is more than likely implicated in many different diseases, but its role is unclear for most of them.
M. hominis is implicated in pelvic inflammatory disease, which may cause
ectopic pregnancy. Recent data shows an increase in reported post-operative CNS infections caused by
Mycoplasma hominis, likely due to the more extensive use of advanced diagnostic methods like PCR and DNA sequencing, especially when routine cultures fail to detect bacterial growth.
Incubation period The incubation period of
M. hominis is unknown.
Treatment Many antibiotics kill bacteria by weakening the cell wall. However, mycoplasma bacteria lack this cellular structure causing some antibiotics, like penicillin, to be ineffective treatment options. Oral tetracyclines have historically been the drugs of choice for use against urogenital and systemic infections due to
M. hominis. In locations and patient populations where tetracycline resistance or treatment failures are common, other drugs such as fluoroquinolones should be considered guided by
in vitro susceptibility data when possible. Recent epidemiologic studies demonstrate that 18% of
Mycoplasma hominis are resistant to ciprofloxacin and 61% are resistant to azithromycin. Resistance to minocycline is 6%. Some infections may be treated by a single antibiotic. In other cases such as severe
M. hominis infections occurring in immunocompromised patients, combination of drugs usually active against the mycoplasmas have been recommended. In those cases, guidelines for optimal therapy remain to be established. Current therapeutic considerations are based only upon case reports. ==Genome studies==